FLUCELVAX TETRA (vaccin grippal quadrivalent, inactivé, préparé sur cultures cellulaire...)

• Key points

Favourable opinion for reimbursement in prophylaxis of influenza in adults and children from 9 years of age for whom influenza vaccination is recommended

• What therapeutic improvement?

No clinical added value.

• Role in the care pathway?

In France, vaccination against seasonal influenza is recommended in all people aged 65 years and over and in the following special populations (see vaccine schedule):

- pregnant women, regardless of the trimester of pregnancy;

- people, from 6 months of age, with conditions promoting the onset of serious influenza complications;

- obese people;

- people staying in follow-on care facilities and medical-social care home residents;

- families of infants under 6 months of age with serious influenza risk factors, as well as the families of immunocompromised individuals;

- professionals in regular and prolonged contact with individuals with a severe influenza risk, in particular healthcare professionals and flight crews.

Role of the medicinal product in the care pathway

FLUCELVAC TETRA may be used in accordance with its MA in the context of current vaccine recommendations, aimed at preventing serious forms and seasonal influenza-related deaths.